Peptides in melanoma therapy

Current Pharmaceutical Design

Volumn 18, Issue 6, 2012, Pages 820-831

  Mocellin, Simone ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Diagnosis; Immunotherapy; Melanoma; Peptide; Therapy; Vaccine

Indexed keywords

ALPHA INTERFERON; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; MELAN A; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN PRESENTING CELL; CANCER CELL; CANCER IMMUNIZATION; CYTOTOXIC T LYMPHOCYTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MELANOMA; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

CANCER VACCINES; DRUG DESIGN; HUMANS; MELANOMA; PEPTIDES; SKIN NEOPLASMS;

EID: 84856508354     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799277734     Document Type: Review

References (160)

1. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411(6835): 380-4.
2. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001; 50(1): 3-15.
3. Dudek NL, Perlmutter P, Aguilar MI, et al. Epitope discovery and their use in peptide based vaccines. Curr Pharm Des 2011; 16(28): 3149-57.
4. Mocellin S, Pilati P, Nitti D. Peptide-based anticancer vaccines: recent advances and future perspectives. Curr Med Chem 2009; 16(36): 4779-96.
5. Pietersz GA, Pouniotis DS, Apostolopoulos V. Design of peptidebased vaccines for cancer. Curr Med Chem 2006; 13(14): 1591-607.
6. Eggermont AM. Immunotherapy: Vaccine trials in melanoma -- time for reflection. Nat Rev Clin Oncol 2009; 6(5): 256-8.
7. Ray S, Chhabra A, Mehrotra S, et al. Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. Clin Dermatol 2009; 27(6): 603-13.
8. Mocellin S, Mandruzzato S, Bronte V, et al. Part I: Vaccines for solid tumours. Lancet Oncol 2004; 5(11): 681-9.
9. Talebi T, Weber JS. Peptide vaccine trials for melanoma: preclinical background and clinical results. Semin Cancer Biol 2003; 13(6): 431-8.
10. Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 2006; 12(10): 3064-9.
11. Tsuruma T, Hata F, Furuhata T, et al. Peptide-based vaccination for colorectal cancer. Expert Opin Biol Ther 2005; 5(6): 799-807.
12. Mocellin S, Rossi CR, Lise M, Nitti D. Colorectal cancer vaccines: principles, results, and perspectives. Gastroenterology 2004; 127(6): 1821-37.
13. Anderson KS. Tumor vaccines for breast cancer. Cancer Invest 2009; 27(4): 361-8.
14. Disis ML, Salazar LG, Knutson KL. Peptide-based vaccines in breast cancer. Breast Dis 2004; 20: 3-11.
15. Rosenberg SA, Zhai Y, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998; 90(24): 1894-900.
16. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18(23): 3964-73.
17. Karbach J, Gnjatic S, Bender A, et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int J Cancer 2011; 126(4): 909-18.
18. Walker EB, Miller W, Haley D, et al. Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood. Clin Cancer Res 2009; 15(7): 2541-51.
19. Walker EB, Haley D, Miller W, et al. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin Cancer Res 2004; 10(2): 668-80.
20. Smith JW, 2nd, Walker EB, Fox BA, et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol 2003; 21(8): 1562-73.
21. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4(3): 321-7.
22. Knutson KL, dela Rosa C, Disis ML. Laboratory analysis of T-cell immunity. Front Biosci 2006; 11: 1932-44.
23. Wang E, Phan GQ, Marincola FM. T-cell-directed cancer vaccines: the melanoma model. Expert Opin Biol Ther 2001; 1(2): 277-90.
24. Townsend AR, Rothbard J, Gotch FM, et al. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986; 44(6): 959-68.
25. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254(5038): 1643-7.
26. Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992; 176(5): 1453-7.
27. Kanodia S, Kast WM. Peptide-based vaccines for cancer: realizing their potential. Expert Rev Vaccines 2008; 7(10): 1533-45.
28. Provenzano M, Panelli MC, Mocellin S, et al. MHC-peptide specificity and T-cell epitope mapping: where immunotherapy starts. Trends Mol Med 2006; 12(10): 465-72.
29. Van Der Bruggen P, Zhang Y, Chaux P, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002; 188: 51-64.
30. Paschen A, Eichmuller S, Schadendorf D. Identification of tumor antigens and T-cell epitopes, and its clinical application. Cancer Immunol Immunother 2004; 53(3): 196-203.
31. Liu R, Enstrom AM, Lam KS. Combinatorial peptide library methods for immunobiology research. Exp Hematol 2003; 31(1): 11-30.
32. Tsurui H, Takahashi T. Prediction of T-cell epitope. J Pharmacol Sci 2007; 105(4): 299-316.
33. Schumacher TN, De Bruijn ML, Vernie LN, et al. Peptide selection by MHC class I molecules. Nature 1991; 350(6320): 703-6.
34. Schumacher TN, Heemels MT, Neefjes JJ, et al. Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell 1990; 62(3): 563-7.
35. Keilholz U, Martus P, Scheibenbogen C. Immune monitoring of Tcell responses in cancer vaccine development. Clin Cancer Res 2006; 12(7 Pt 2): 2346s-2352s.
36. Lyerly HK. Quantitating cellular immune responses to cancer vaccines. Semin Oncol 2003; 30(3 Suppl 8): 9-16.
37. Guermonprez P, Valladeau J, Zitvogel L, et al. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002; 20: 621-67.
38. Hanisch FG, Ninkovic T. Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine. Curr Protein Pept Sci 2006; 7(4): 307-15.
39. Kuckelkorn U, Ruppert T, Strehl B, et al. Link between organspecific antigen processing by 20S proteasomes and CD8(+) T cellmediated autoimmunity. J Exp Med 2002; 195(8): 983-90.
40. Liu JQ, Bai XF. Overcoming immune evasion in T cell therapy of cancer: lessons from animal models. Curr Mol Med 2008; 8(1): 68-75.
41. Singh R, Paterson Y. Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res 2007; 67(5): 1887-92.
42. Fikes JD, Sette A. Design of multi-epitope, analogue-based cancer vaccines. Expert Opin Biol Ther 2003; 3(6): 985-93.
43. DeLeo AB, Whiteside TL. Development of multi-epitope vaccines targeting wild-type sequence p53 peptides. Expert Rev Vaccines 2008; 7(7): 1031-40.
44. Borbulevych OY, Baxter TK, Yu Z, et al. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J Immunol 2005; 174(8): 4812-20.
45. Chen JL, Stewart-Jones G, Bossi G, et al. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med 2005; 201(8): 1243-55.
46. Meijer SL, Dols A, Jensen SM, et al. Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide. J Immunother 2007; 30(5): 533-43.
47. Clay TM, Custer MC, McKee MD, et al. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J Immunol 1999; 162(3): 1749-55.
48. Lee KH, Wang E, Nielsen MB, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999; 163(11): 6292-300.
49. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res 2003; 9(8): 2973-80.
50. Hersey P, Menzies SW, Coventry B, et al. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunol Immunother 2005; 54(3): 208-18.
51. Mocellin S, Rossi CR, Nitti D. Cancer vaccine development: on the way to break immune tolerance to malignant cells. Exp Cell Res 2004; 299(2): 267-78.
52. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364(22): 2119-27.
53. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102(7): 493-501.
54. Di Pucchio T, Pilla L, Capone I, et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 2006; 66(9): 4943-51.
55. Cole DK, Edwards ES, Wynn KK, et al. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol 2011; 185(4): 2600-10.
56. Zirlik KM, Zahrieh D, Neuberg D, Gribben JG. Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide. Blood 2006; 108(12): 3865-70.
57. Tangri S, Ishioka GY, Huang X, et al. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 2001; 194(6): 833-46.
58. Butler NS, Theodossis A, Webb AI, et al. Prevention of cytotoxic T cell escape using a heteroclitic subdominant viral T cell determinant. PLoS Pathog 2008; 4(10): e1000186.
59. Slansky JE, Rattis FM, Boyd LF, et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000; 13(4): 529-38.
60. Dyall R, Bowne WB, Weber LW, et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998; 188(9): 1553-61.
61. Scardino A, Alimandi M, Correale P, et al. A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge. Cancer Res 2007; 67(14): 7028-36.
62. Hou Y, Kavanagh B, Fong L. Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumorassociated antigen. J Immunol 2008; 180(3): 1526-34.
63. Chiong B, Wong R, Lee P, et al. Characterization of long-term effector-memory T-cell responses in patients with resected highrisk melanoma receiving a melanoma Peptide vaccine. J Immunother 2004; 27(5): 368-79.
64. Frank C, Hundemer M, Ho AD, et al. Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma. Leuk Lymphoma 2008; 49(4): 779-85.
65. Brown ME, Miao H, McKee MD. Recognition of carcinoembryonic antigen peptide and heteroclitic peptide by peripheral blood T lymphocytes. J Immunother 2007; 30(3): 350-8.
66. Speiser DE, Baumgaertner P, Voelter V, et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci USA 2008; 105(10): 3849-54.
67. Stuge TB, Holmes SP, Saharan S, et al. Diversity and recognition efficiency of T cell responses to cancer. PLoS Med 2004; 1(2): e28.
68. Knittelfelder R, Riemer AB, Jensen-Jarolim E. Mimotope vaccination-- from allergy to cancer. Expert Opin Biol Ther 2009; 9(4): 493-506.
69. Blake J, Johnston JV, Hellstrom KE, et al. Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes. J Exp Med 1996; 184(1): 121-30.
70. Sharav T, Wiesmuller KH, Walden P. Mimotope vaccines for cancer immunotherapy. Vaccine 2007; 25(16): 3032-7.
71. Wang Y, Rubtsov A, Heiser R, et al. Using a baculovirus display library to identify MHC class I mimotopes. Proc Natl Acad Sci USA 2005; 102(7): 2476-81.
72. Luo W, Ko E, Hsu JC, et al. Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J Immunol 2006; 176(10): 6046-54.
73. Wierzbicki A, Gil M, Ciesielski M, et al. Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells. J Immunol 2008; 181(9): 6644-53.
74. van Stipdonk MJ, Badia-Martinez D, Sluijter M, et al. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res 2009; 69(19): 7784-92.
75. Wagner S, Krepler C, Allwardt D, et al. Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine. Clin Cancer Res 2008; 14(24): 8178-83.
76. Latzka J, Gaier S, Hofstetter G, et al. Specificity of Mimotope- Induced Anti-High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) Antibodies Does Not Ensure Biological Activity. PLoS One 2011; 6(5): e19383.
77. Tumenjargal S, Gellrich S, Linnemann T, et al. Anti-tumor immune responses and tumor regression induced with mimotopes of a tumor-associated T cell epitope. Eur J Immunol 2003; 33(11): 3175-85.
78. Guichard G, Zerbib A, Le Gal FA, et al. Melanoma peptide MART- 1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumorinfiltrating lymphocytes. J Med Chem 2000; 43(20): 3803-8.
79. Webb AI, Dunstone MA, Williamson NA, et al. T cell determinants incorporating beta-amino acid residues are protease resistant and remain immunogenic in vivo. J Immunol 2005; 175(6): 3810-8.
80. Steer DL, Lew RA, Perlmutter P, et al. Beta-amino acids: versatile peptidomimetics. Curr Med Chem 2002; 9(8): 811-22.
81. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007; 6(5): 404-14.
82. Marschutz MK, Zauner W, Mattner F, et al. Improvement of the enzymatic stability of a cytotoxic T-lymphocyte-epitope model peptide for its oral administration. Peptides 2002; 23(10): 1727-33.
83. McGregor DP. Discovering and improving novel peptide therapeutics. Curr Opin Pharmacol 2008; 8(5): 616-9.
84. Dell K, Koesters R, Gissmann L. Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors. Int J Cancer 2006; 118(2): 364-72.
85. Tindle RW, Fernando GJ, Sterling JC, Frazer IH. A public Thelper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci USA 1991; 88(13): 5887-91.
86. Karanikas V, Colau D, Baurain JF, et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001; 61(9): 3718-24.
87. Karanikas V, Hwang LA, Pearson J, et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan- MUC1 fusion protein. J Clin Invest 1997; 100(11): 2783-92.
88. White K, Kearns P, Toth I, Hook S. Increased adjuvant activity of minimal CD8 T cell peptides incorporated into lipid-core-peptides. Immunol Cell Biol 2004; 82(5): 517-22.
89. Brandt ER, Sriprakash KS, Hobb RI, et al. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat Med 2000; 6(4): 455-9.
90. Sadler K, Zeng W, Jackson DC. Synthetic peptide epitope-based polymers: controlling size and determining the efficiency of epitope incorporation. J Pept Res 2002; 60(3): 150-8.
91. Fitzmaurice CJ, Brown LE, McInerney TL, Jackson DC. The assembly and immunological properties of non-linear synthetic immunogens containing T-cell and B-cell determinants. Vaccine 1996; 14(6): 553-60.
92. Slingluff CL, Jr., Petroni GR, Yamshchikov GV, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 2004; 22(22): 4474-85.
93. Slingluff CL, Jr., Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocytemacrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003; 21(21): 4016-26.
94. Slingluff CL, Jr., Petroni GR, Olson W, et al. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol 2008; 26(30): 4973-80.
95. Scheibenbogen C, Schmittel A, Keilholz U, et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother 2000; 23(2): 275-81.
96. Phan GQ, Touloukian CE, Yang JC, et al. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother 2003; 26(4): 349-56.
97. Rosenberg SA, Sherry RM, Morton KE, et al. Altered CD8(+) Tcell responses when immunizing with multiepitope peptide vaccines. J Immunother 2006; 29(2): 224-31.
98. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23(4): 741-50.
99. Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev 2011; 241(1): 104-18.
100. Gajewski TF, Meng Y, Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006; 213: 131-45.
101. Gabrilovich D. Mechanisms and functional significance of tumourinduced dendritic-cell defects. Nat Rev Immunol 2004; 4(12): 941-52.
102. Perales MA, Blachere NE, Engelhorn ME, et al. Strategies to overcome immune ignorance and tolerance. Semin Cancer Biol 2002; 12(1): 63-71.
103. Shashidharamurthy R, Bozeman EN, Patel J, et al. Immunotherapeutic strategies for cancer treatment: A novel protein transfer approach for cancer vaccine development. Med Res Rev 2011.
104. Zwirner NW, Croci DO, Domaica CI, Rabinovich GA. Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells. Curr Pharm Des 2010; 16(3): 255-67.
105. Mocellin S. Metabolic immune restraints: implications for anticancer vaccines. Curr Pharm Des 2010; 16(3): 277-91.
106. Higgins JP, Bernstein MB, Hodge JW. Enhancing immune responses to tumor-associated antigens. Cancer Biol Ther 2009; 8(15): 1440-9.
107. Bronte V, Mocellin S. Suppressive influences in the immune response to cancer. J Immunother 2009; 32(1): 1-11.
108. Mocellin S, Nitti D. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines. Med Res Rev 2008; 28(3): 413-44.
109. Rescigno M, Avogadri F, Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. Biochim Biophys Acta 2007; 1776(1): 108-23.
110. Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 2006; 6(8): 613-25.
111. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274(5284): 94-6.
112. Anichini A, Molla A, Mortarini R, et al. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 1999; 190(5): 651-67.
113. Lally KM, Mocellin S, Ohnmacht GA, et al. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int J Cancer 2001; 93(6): 841-7.
114. Nielsen MB, Monsurro V, Migueles SA, et al. Status of activation of circulating vaccine-elicited CD8+ T cells. J Immunol 2000; 165(4): 2287-96.
115. Yee C, Savage PA, Lee PP, et al. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide- MHC tetramers. J Immunol 1999; 162(4): 2227-34.
116. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5(6): 677-85.
117. Monsurro V, Nagorsen D, Wang E, et al. Functional heterogeneity of vaccine-induced CD8(+) T cells. J Immunol 2002; 168(11): 5933-42.
118. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396(6712): 643-9.
119. Jager E, Ringhoffer M, Altmannsberger M, et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997; 71(2): 142-7.
120. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
121. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16(10): 487-94.
122. Cormier JN, Panelli MC, Hackett JA, et al. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer 1999; 80(5): 781-90.
123. Wang E, Marincola FM. A natural history of melanoma: serial gene expression analysis. Immunol Today 2000; 21(12): 619-23.
124. Wang E, Panelli MC, Marincola FM. Gene profiling of immune responses against tumors. Curr Opin Immunol 2005; 17(4): 423-7.
125. Wang E, Miller LD, Ohnmacht GA, et al. High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000; 18(4): 457-9.
126. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet 1999; 21(1 Suppl): 33-7.
127. Mocellin S, Wang E, Panelli M, et al. DNA array-based gene profiling in tumor immunology. Clin Cancer Res 2004; 10(14): 4597-606.
128. Wolfel T, Klehmann E, Muller C, et al. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989; 170(3): 797-810.
129. Pockaj BA, Sherry RM, Wei JP, et al. Localization of 111indiumlabeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994; 73(6): 1731-7.
130. Dubey P, Su H, Adonai N, et al. Quantitative imaging of the T cell antitumor response by positron-emission tomography. Proc Natl Acad Sci USA 2003; 100(3): 1232-7.
131. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401(6754): 708-12.
132. Lee KH, Panelli MC, Kim CJ, et al. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 1998; 161(8): 4183-94.
133. Panelli MC, Bettinotti MP, Lally K, et al. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. J Immunol 2000; 164(8): 4382-92.
134. Yee C, Riddell SR, Greenberg PD. In vivo tracking of tumorspecific T cells. Curr Opin Immunol 2001; 13(2): 141-6.
135. Jager E, Maeurer M, Hohn H, et al. Clonal expansion of Melan Aspecific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer 2000; 86(4): 538-47.
136. Panelli MC, Riker A, Kammula U, et al. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. J Immunol 2000; 164(1): 495-504.
137. Kammula US, Lee KH, Riker AI, et al. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 1999; 163(12): 6867-75.
138. Ohnmacht GA, Wang E, Mocellin S, et al. Short-term kinetics of tumor antigen expression in response to vaccination. J Immunol 2001; 167(3): 1809-20.
139. Marincola FM, Wang E, Herlyn M, et al. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 2003; 24(6): 335-42.
140. Galgani M, Di Giacomo A, Matarese G, La Cava A. The Yin and Yang of CD4(+) regulatory T cells in autoimmunity and cancer. Curr Med Chem 2009; 16(35): 4626-31.
141. Beyer M, Schultze JL. Regulatory T cells: major players in the tumor microenvironment. Curr Pharm Des 2009; 15(16): 1879-92.
142. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9(3): 162-74.
143. Marigo I, Dolcetti L, Serafini P, et al. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008; 222: 162-79.
144. Schreiber TH, Raez L, Rosenblatt JD, Podack ER. Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin Immunol 2011; 22(3): 105-12.
145. Tabi Z, Man S. Challenges for cancer vaccine development. Adv Drug Deliv Rev 2006; 58(8): 902-15.
146. Mocellin S. Cancer vaccines: the challenge of developing an ideal tumor killing system. Front Biosci 2005; 10: 2285-305.
147. Mocellin S, Ohnmacht GA, Wang E, Marincola FM. Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. Int J Cancer 2001; 93(2): 236-42.
148. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother 2001; 24(5): 392-407.
149. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLAA1. Int J Cancer 1999; 80(2): 219-30.
150. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190(11): 1669-78.
151. Wang F, Bade E, Kuniyoshi C, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999; 5(10): 2756-65.
152. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) proprogenitor-derived dendritic cell vaccine. Cancer Res 2001; 61(17): 6451-8.
153. Lee P, Wang F, Kuniyoshi J, et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001; 19(18): 3836-47.
154. Pittet MJ, Speiser DE, Lienard D, et al. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res 2001; 7(3 Suppl): 796s-803s.
155. Slingluff CL, Jr., Yamshchikov G, Neese P, et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 2001; 7(10): 3012-24.
156. Yamshchikov GV, Barnd DL, Eastham S, et al. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int J Cancer 2001; 92(5): 703-11.
157. Coulie PG, Karanikas V, Lurquin C, et al. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 2002; 188: 33-42.
158. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002; 195(10): 1279-88.
159. Weber J, Sondak VK, Scotland R, et al. Granulocyte-macrophagecolony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 2003; 97(1): 186-200.
160. Whiteside TL, Zhao Y, Tsukishiro T, et al. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin Cancer Res 2003; 9(2): 641-9.